Race Oncology Limited
RAONF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$451.73M
Close$
$-1.74
166.9% downside
Current Fair Value
166.9% downsideOvervalued by 166.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $451.73 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.03 |
| Beta | 1.91 |
| Outstanding Shares | 171,483,903 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -29.32 |
|---|---|
| PEG | -91.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Race Oncology Limited
5 employees
CEO: Daniel Tillett
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity ass...